News

Bowel Screening Can Save Lives, So Why Are Australians Still Missing Their Tests?

By 21/09/2026No Comments

Australia has a free, evidence-based bowel cancer screening program capable of detecting disease before symptoms develop. The test can be completed privately at home, takes only a few minutes and does not require dietary restrictions, bowel preparation or a medical appointment. Yet a majority of eligible Australians still do not complete and return their test when invited.

According to figures highlighted by University of Sydney researchers, participation among eligible Australians was 41.7% during 2022–2023. In practical terms, that means millions of opportunities for prevention or earlier diagnosis were missed. The gap is especially striking because bowel cancer is common, screening is free, and early detection can substantially improve treatment options and outcomes.

Why, then, do so many kits remain unopened, forgotten or discarded? The answer is more complex than a lack of awareness. Behavioural friction, embarrassment, misconceptions about risk, competing priorities, language and cultural barriers, distrust, administrative problems and uncertainty about what happens after a positive result can all influence participation. This analysis examines those barriers and what Australia can do to turn a mailed kit into a completed screening pathway.

Article index

Why bowel screening matters

Bowel cancer, also known as colorectal cancer, develops in the colon or rectum. Many cases begin as polyps, which are growths arising from the bowel lining. Most polyps do not cause symptoms and not every polyp becomes cancerous, but certain types can acquire progressive cellular changes over time. Detecting and removing clinically significant polyps can interrupt that pathway before an invasive cancer develops.

Screening can also identify bleeding from an existing cancer at an earlier stage, when treatment is generally less complex and the probability of successful treatment is higher. This is the defining purpose of screening: to look for evidence of disease in people who feel well and have no recognised symptoms.

The population impact is substantial. Randomised evidence has shown that regular faecal occult blood testing can reduce deaths from colorectal cancer. Long-term research also indicates that screening can reduce incidence, partly because subsequent colonoscopy allows precancerous lesions to be identified and removed.

However, a screening program produces benefit only when people move through the entire pathway. A kit that remains in a bathroom drawer has no preventive value. Likewise, a positive result that is not medically assessed represents an incomplete screen rather than successful early detection.

How Australia’s screening program works

The National Bowel Cancer Screening Program offers eligible Australians aged 45 to 74 a free faecal immunochemical test, or FIT, every two years. People aged 50 to 74 are generally mailed a kit automatically. Those aged 45 to 49 can request their first free kit through the National Cancer Screening Register; after participating, they can receive subsequent invitations at the appropriate interval.

The FIT looks for very small quantities of human blood in stool that may not be visible. The person collects small samples from separate bowel motions using the supplied collection device, places the samples in the tubes and returns them in the reply-paid packaging. No sedative, laxative bowel preparation or visit to a clinic is needed.

A negative result means blood was not detected at the test threshold in those samples. It does not guarantee that a person has no cancer, polyp or other bowel disease, which is why repeating screening every two years matters. A positive result means blood was detected and the cause needs investigation. It does not mean the person definitely has bowel cancer.

Direct Endoscopy’s detailed guide to bowel cancer screening in Australia explains eligibility, completing the test, interpreting results and why a positive FIT commonly leads to colonoscopy.

The participation gap

Australian participation has remained well below the level required to realise the program’s full potential. The 41.7% figure reported for 2022–2023 indicates that fewer than half of eligible invitees completed the test within the monitored period. Participation also varies by age, sex, location, socioeconomic circumstances, cultural background and previous screening behaviour.

That variation is important. A national average can conceal groups with much lower participation and therefore fewer opportunities for early detection. It can also conceal a group of regular screeners who return each kit promptly, alongside people who have never participated. The public-health challenge is not merely to generate one more test; it is to establish repeated participation at the recommended interval.

Low participation is sometimes described as public indifference, but that interpretation is too simplistic. Screening behaviour results from an interaction between the individual, the test, the invitation system and the health service that follows it. A person may believe screening is valuable yet still fail to act because the kit was sent to an old address, the instructions feel confusing, the collection process seems unpleasant or everyday demands continually take priority.

“I feel well” is not a reason to delay screening

One of the program’s greatest communication challenges is that screening asks healthy people to act before they perceive a problem. Many people use symptoms as their internal signal for seeking care: if there is no pain, bleeding or change in bowel habit, they assume there is no need for testing.

That reasoning is understandable but does not fit the biology of bowel cancer. Polyps usually cause no symptoms, and early colorectal cancers may cause none. By the time obvious symptoms develop, a cancer may be more advanced. Screening is specifically designed to operate during this silent period.

Good health habits can also create false reassurance. Being active, eating well and having no family history may reduce risk, but none of these factors eliminates it. Most people diagnosed with bowel cancer do not necessarily have a dramatic hereditary history. Age itself is an important risk factor, which is why a population program invites asymptomatic people within a defined age range.

Effective messages should therefore avoid alarm while correcting the central misconception: the kit is not sent because the government thinks a person is sick. It is sent because screening is most useful before illness is apparent.

The power of practical friction

Health decisions are not made in ideal conditions. Kits arrive among bills, advertising and other mail. A person may intend to complete the test after reading the instructions, then put it aside until a more convenient time. That intention can persist for months without becoming action.

Behavioural scientists describe this as an intention–action gap. Every additional step creates friction: opening the envelope, reading the information, storing the kit, remembering to use it during a bowel motion, collecting a second sample, recording details and posting it. None is individually difficult, but the combined task competes with work, caring responsibilities and routine disruption.

Administrative friction can be just as important. Automatic mailing depends on accurate contact information. People who move frequently, live between addresses or do not update Medicare details may never receive the kit. Others may lose it, allow it to expire or assume a replacement will be difficult to obtain. People aged 45 to 49 face an additional behavioural step because they must request their first kit rather than receiving one automatically.

These barriers suggest that stronger education alone will not be enough. Reminders, simple replacement pathways, prompts from trusted clinicians and invitations timed around routine health encounters can make the desired action easier.

Discomfort, disgust and embarrassment

Faecal sampling confronts strong social taboos. Some people dislike discussing bowel motions, feel embarrassed by the test or worry that collection will be messy and unhygienic. Even when they intellectually accept the health benefit, an immediate emotional response can lead them to avoid opening the kit.

The design of FIT has reduced much of the burden associated with older stool tests. Only a small sample is required, and the kit provides collection materials and sealed tubes. The process can usually be completed quickly and privately. Nevertheless, campaigns that describe the test only as “easy” risk dismissing genuine discomfort.

A better approach acknowledges the awkwardness and provides specific, practical reassurance. Clear diagrams, short demonstration videos and neutral language can reduce uncertainty. Humour may help some audiences, but communication must remain respectful and should not trivialise cancer or alienate people whose cultural norms make bowel health especially private.

Normalising the test is also powerful. When family members, pharmacists, GPs and public figures speak matter-of-factly about completing it, faecal sampling can be reframed as a routine preventive behaviour rather than an exceptional or shameful act.

Fear and avoidance

Some non-participation is driven not by underestimating risk but by fearing the result. People may worry that the test will reveal cancer, that treatment will be debilitating, or that a positive result will force them into an invasive procedure. Avoidance can temporarily reduce anxiety, which reinforces postponement.

The paradox is that delaying screening does not prevent cancer. It removes an opportunity to find it earlier. A positive FIT is not a cancer diagnosis; blood can arise from polyps, haemorrhoids, inflammation and other conditions. Colonoscopy is recommended because the source cannot be determined from the FIT alone.

Communication should explain the pathway before the person tests: what positive and negative results mean, who will contact them, how colonoscopy is arranged and what support is available. Uncertainty often magnifies fear. A transparent pathway allows people to make an informed decision without pretending that follow-up is effortless or risk-free.

Health literacy and misunderstanding

The terms used in bowel screening are not always intuitive. People may encounter “FOBT,” “iFOBT,” “FIT,” “occult blood,” “positive screen” and “colonoscopy” in the same pathway. Some interpret “positive” as confirmation of cancer. Others believe a negative result provides permanent clearance, or that the test is unnecessary after a previous colonoscopy.

Instructions must communicate several concepts at once: the test is for people without symptoms; it detects blood rather than cancer; a positive result needs further investigation; a negative result is not perfect; and screening must be repeated at the recommended interval. Poorly structured information can overwhelm rather than educate.

Plain language does not mean medically inaccurate language. It means presenting the essential action first, defining technical terms and separating screening from diagnosis. Visual instructions should be accessible to people with limited literacy or vision, and digital resources should supplement rather than replace printed and clinician-delivered information.

Cultural and language barriers

Australia’s population is linguistically and culturally diverse, yet a centrally mailed kit can assume familiarity with preventive screening, postal systems and written health instructions. People from countries without an organised screening program may not understand why a government service is sending a stool test to someone who feels well.

Translated materials are essential but are not the complete solution. Literal translation may not address beliefs about cancer, fatalism, privacy, gender, family decision-making or trust in institutions. Community-led education delivered through culturally credible organisations and health professionals can create a context in which the written instructions make sense.

Aboriginal and Torres Strait Islander participation must be considered through the broader experience of health-care access, cultural safety and institutional trust. Effective programs should be developed with communities, not merely translated for them. Aboriginal Community Controlled Health Services and Indigenous health workers can provide trusted conversations, practical assistance and continuity into follow-up care.

The objective is not to categorise entire communities as reluctant. It is to recognise that a uniform invitation will not produce equitable participation when language, health-system familiarity and access to trusted care are unequal.

Geographic and socioeconomic inequity

The home test itself is free, but the wider pathway can carry costs. A person with casual employment may worry about time away from work if follow-up is required. Rural patients may face travel, accommodation and limited access to colonoscopy. People with caring duties may struggle to arrange transport and supervision after sedation.

These future burdens can affect the initial decision to screen. If a person believes that a positive result will lead to an unaffordable or inaccessible process, not testing can appear to postpone a problem they feel unable to manage.

Socioeconomic disadvantage can also increase address instability, reduce access to primary care and place preventive tasks below immediate needs such as housing, food and employment. Low participation in this context is not adequately addressed by a message telling people to be more responsible.

A successful program therefore requires capacity beyond the kit: affordable primary care, timely diagnostic services, navigation support, regional pathways and communication that explains likely costs and logistics. Participation should be measured alongside timely follow-up, because inequity can emerge at every stage.

Why GPs and trusted clinicians matter

A recommendation from a GP or another trusted health professional can convert an impersonal mail-out into a relevant health action. Clinicians can confirm eligibility, explain why testing matters despite the absence of symptoms, correct misconceptions and help obtain a replacement kit.

Primary care can also prevent inappropriate screening. A patient who reports rectal bleeding, iron-deficiency anaemia, unexplained weight loss or persistent bowel change should not simply be told to complete a screening FIT and wait. Symptoms require clinical assessment and may justify diagnostic investigation regardless of the screening result.

Electronic prompts and preventive health checks can help clinicians identify patients who are overdue. The conversation does not need to be long: a clear, personalised recommendation and a plan for completing the kit can be more effective than generic information. Practices can also follow up results and help ensure positive tests progress to colonoscopy.

What a positive FIT result means

A positive FIT means that blood was detected in at least one returned sample. It is an abnormal screening result, not a diagnosis. Possible explanations include bowel polyps, haemorrhoids, diverticular disease, inflammation and colorectal cancer. The result cannot identify the source or determine whether a lesion is benign.

The appropriate response is to arrange timely medical review. Repeating the FIT to see whether it becomes negative is generally not a substitute for investigating the original positive result. Bleeding from polyps or cancer can be intermittent, so a subsequent negative sample may provide false reassurance.

A GP will consider the result alongside symptoms, medical history, medicines, family history and fitness for colonoscopy. The next step is commonly referral for colonoscopy, which allows the bowel lining to be examined directly and suspicious tissue to be sampled.

Colonoscopy after a positive result

Screening benefit depends on access to high-quality diagnostic colonoscopy after a positive FIT. During a colonoscopy, a flexible instrument with a camera is used to inspect the colon and rectum. Polyps can often be removed during the procedure and tissue samples can be sent for pathology.

Patients need bowel preparation beforehand so the bowel lining can be seen clearly. Sedation is commonly used, and arrangements are required for transport and post-procedure supervision. Colonoscopy has risks, including bleeding, cardiopulmonary complications related to sedation and, rarely, perforation. The clinician should explain these in the context of the indication and the patient’s health.

Not every positive FIT reveals cancer. Many identify polyps or non-cancerous sources of bleeding, and some colonoscopies do not find a significant abnormality. The value of the procedure lies in resolving uncertainty, detecting important lesions and enabling removal or biopsy where appropriate.

If polyps or biopsies are taken, the final interpretation may depend on pathology. Direct Endoscopy’s guide to colonoscopy results, polyps and biopsies explains immediate findings, pathology timing and possible surveillance recommendations.

Screening is not a test for symptoms

The national program is designed for people who do not have bowel symptoms. This distinction is essential because a FIT can miss lesions that are not bleeding at the time of sampling. A negative result must not be used to dismiss ongoing clinical concerns.

Speak with a GP if you have:

  • blood in the stool or rectal bleeding;
  • a new and persistent change in bowel habit;
  • unexplained abdominal pain or bloating;
  • unexplained weight loss;
  • fatigue, iron deficiency or iron-deficiency anaemia;
  • a persistent sensation of incomplete bowel emptying; or
  • bowel symptoms combined with a significant family history.

These symptoms are frequently caused by conditions other than cancer, but persistence, progression and associated clinical findings matter. People younger than the program age should also seek assessment when symptoms are concerning. The recent increase in early-onset bowel cancer reinforces that age should inform clinical probability without becoming a reason to ignore warning signs.

How participation could be improved

Australia is unlikely to close the screening gap with awareness campaigns alone. A more effective strategy would address barriers at several levels.

Make the next action unmistakable

Invitations should lead with a short, concrete instruction and explain why the test is needed when a person feels well. Instructions can use diagrams, video and multiple languages without burying the essential steps in lengthy material.

Use reminders that support action

Text messages, letters and primary-care prompts can remind people before kits expire. Messages are likely to be more effective when they identify a manageable action, such as placing the kit in the bathroom or completing it with the next suitable bowel motion, rather than repeating general cancer statistics.

Reduce replacement and address barriers

People should be able to update details and request a replacement kit easily. Health services and community organisations can help patients navigate the register, particularly where digital access or English proficiency is limited.

Use trusted messengers

GPs, pharmacists, nurses, Indigenous health workers and community leaders can make screening personally relevant. Recommendation systems should support culturally safe, multilingual and locally designed communication rather than relying on a single national message.

Explain the complete pathway

People need to know what happens after both negative and positive results. Clear information about colonoscopy, likely timelines, transport and costs can reduce uncertainty. Navigation support is especially important for patients facing geographic or socioeconomic barriers.

Measure completion, not just kit return

Program success should include repeat participation, timely assessment of positive results and equitable access to colonoscopy. Increasing the number of returned kits without adequate diagnostic capacity would leave an important part of the pathway unresolved.

What eligible Australians can do now

If a bowel screening kit has arrived, check the expiry date and complete it according to the instructions even if you feel entirely well. Store it somewhere visible and practical rather than filing it with paperwork. If it is lost, damaged or expired, request a replacement through the National Cancer Screening Register.

People aged 45 to 49 who have not yet participated can request their first free kit. Those aged 50 to 74 should check that Medicare contact information is current if a kit has not arrived when expected. Screening should then be repeated every two years while eligible unless a clinician recommends a different plan.

Tell your GP about previous polyps, inflammatory bowel disease and relevant family history. These factors can alter the appropriate screening or surveillance pathway. Direct Endoscopy’s article on family history and bowel cancer screening outlines what information is useful and why some people require earlier or more intensive assessment.

Most importantly, do not substitute screening for medical review of symptoms. Screening is preventive care for people without symptoms; diagnostic assessment addresses a current concern.

When Direct Endoscopy may be able to help

Direct Endoscopy provides colonoscopy services across several Melbourne locations. A colonoscopy may be recommended after a positive bowel screening result, to investigate persistent symptoms or as part of an individual surveillance plan for previous polyps, inflammatory bowel disease or significant family history.

In most circumstances, a referral from a GP or specialist is required. The referral helps communicate the clinical indication and relevant medical history so the procedure can be planned appropriately. Patients can review Direct Endoscopy’s clinic locations and appointment information before arranging care.

Australia does not lack an effective bowel screening test. It faces a gap between availability and completion, and between a positive result and definitive investigation. Closing that gap requires individual action, trusted clinical recommendation, culturally appropriate communication and a health system capable of providing timely follow-up.

The kit may be small, but its role is significant: it can begin a process that detects a precancerous polyp or identifies cancer before symptoms appear. Completing it is not a sign that something is wrong. It is a practical decision to look while earlier intervention may still be possible.

References and further reading

Medical disclaimer: This article provides general information and does not replace individual medical advice. Speak with your GP or treating specialist about symptoms, screening eligibility, abnormal results and the investigation most appropriate for you.

Select Language »